Get the Stockscreener App
50.92
0.27%
-0.142
Qiagen Nv stock is traded at $50.92, with a volume of 1.09M.
It is down -0.27% in the last 24 hours and up +7.77% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
See More
Previous Close:
$51.06
Open:
$51.16
24h Volume:
1.09M
Relative Volume:
0.57
Market Cap:
$10.49B
Revenue:
$2.07B
Net Income/Loss:
$405.37M
P/E Ratio:
26.09
EPS:
1.9513
Net Cash Flow:
$472.50M
1W Performance:
-0.61%
1M Performance:
+7.77%
6M Performance:
+3.98%
1Y Performance:
+26.86%
1-Day Range:
$50.71
$51.59
1-Week Range:
$50.52
$51.71
52-Week Range:
$37.74
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
50.91 | 10.52B | 2.07B | 405.37M | 472.50M | 1.9513 |
|
TMO
Thermo Fisher Scientific Inc
|
509.25 | 198.06B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
216.43 | 155.50B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
618.37 | 51.80B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
124.87 | 36.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
318.94 | 32.29B | 3.11B | 648.81M | 602.27M | 10.88 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
QIAGEN NV : Buy rating from Berenberg - marketscreener.com
QIAGEN Is Unleashing a Powerful Product Expansion Strategy — And It’s Reshaping Growth! - Smartkarma
Goldman Sachs Discloses 3.06% Stake in Qiagen via AFM Filing - TipRanks
Release according to Article 40, Section 1 of the WpHG - TradingView
UBS Adjusts QIAGEN Price Target to $52 From $50, Maintains Neutral Rating - marketscreener.com
Qiagen N.V. $QGEN Shares Sold by Nuance Investments LLC - MarketBeat
Qiagen N : Fourth Quarter 2025 Transcript - marketscreener.com
Entry Recap: Is Qiagen NV backed by strong institutional buyingWeekly Investment Report & Expert Verified Movement Alerts - baoquankhu1.vn
Qiagen targets 9% growth in 2026 growth pillars and $2B by 2028 with new product launches - MSN
Qiagen Q4 Earnings Call Highlights - MarketBeat
Qiagen N.V. (NYSE:QGEN) Q4 2025 Earnings Call Transcript - Insider Monkey
Qiagen (QGEN) PT Raised by JP Morgan Amid Overweight Rating | QG - GuruFocus
JPMorgan Chase & Co. Boosts Qiagen (NYSE:QGEN) Price Target to $60.00 - MarketBeat
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Stifel raises Qiagen stock price target to $50 on growth outlook By Investing.com - Investing.com South Africa
Citigroup Cuts Qiagen (NYSE:QGEN) Price Target to $55.00 - MarketBeat
QGEN Analyst Rating: Citigroup Maintains Neutral, Lowers Price T - GuruFocus
Qiagen (QGEN): Stifel Raises Price Target to $50, Maintains Hold Rating | QGEN Stock News - GuruFocus
Stifel raises Qiagen stock price target to $50 on growth outlook - Investing.com
Qiagen NV (QGEN) PT Raised to $50 at Stifel - StreetInsider
Qiagen: 2025 ended positively, entering 2026 with confidence - marketscreener.com
QGEN's Q4 Earnings Meet Estimates, Revenues Up Y/Y, Stock Down - TradingView
Qiagen Tops 2025 Guidance and Sets Ambitious 2026 Growth Targets - TipRanks
QIAGEN (NYSE: QGEN) tops 2025 targets and guides for at least 5% CER sales growth in 2026 - Stock Titan
QIAGEN NV : Jefferies reaffirms its Buy rating - marketscreener.com
Jefferies Maintains Buy on Qiagen N.V. (QGEN) Feb 2026 - Meyka
Qiagen (QGEN) Exceeds Q4 2025 Expectations with Strong Financial Performance - GuruFocus
Qiagen NV (QGEN) Q4 2025 Earnings Call Highlights: Strong Growth Amidst Challenges - GuruFocus
Qiagen NV (QGEN) Q4 2025 Earnings Call Highlights: Strong Growth Amidst Challenges By GuruFocus - Investing.com Canada
Investors Purchase Large Volume of Call Options on Qiagen (NYSE:QGEN) - MarketBeat
Allianz Asset Management GmbH Purchases 534,527 Shares of Qiagen N.V. $QGEN - MarketBeat
QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars - BioSpace
QIAGEN NV : Jefferies maintains a Buy rating - marketscreener.com
Goldman Sachs Reports 3.11% Stake in QIAGEN via Shares and Derivatives - The Globe and Mail
Qiagen reports Q4 sales USD 540 mln - marketscreener.com
BlackRock Discloses Significant Stake in QIAGEN - The Globe and Mail
Qiagen (QGEN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Qiagen: Q4 Financial Results Overview - Bitget
Qiagen (QGEN) Meets Q4 Earnings Estimates - Yahoo Finance
Qiagen (NYSE:QGEN) Announces Earnings Results - MarketBeat
Qiagen (NYSE:QGEN) Updates Q1 2026 Earnings Guidance - MarketBeat
Qiagen (NYSE:QGEN) Issues FY 2026 Earnings Guidance - MarketBeat
Qiagen: Q4 Earnings Snapshot - kare11.com
Qiagen guides to at least 5% sales growth in 2026 By Investing.com - Investing.com Nigeria
Qiagen guides to at least 5% sales growth in 2026 - Investing.com
Qiagen faces earnings test as analyst estimates slide 15% despite takeover chatter - Investing.com
QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - Pressetext
QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026 - BioSpace
Aug Mood: Should I set a stop loss on Qiagen N.VEarnings Overview Report & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Examining the Future: Qiagen's Earnings Outlook - Benzinga
OTC/DTC Infectious Disease Diagnostics Research Report 2026: Market Strategies, Trends, and Forecasts 2025-2029 - GlobeNewswire Inc.
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):